U.S. flag

An official website of the United States government

NM_000527.5(LDLR):c.1004G>T (p.Gly335Val) AND Cardiovascular phenotype

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Sep 14, 2017
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002401931.2

Allele description [Variation Report for NM_000527.5(LDLR):c.1004G>T (p.Gly335Val)]

NM_000527.5(LDLR):c.1004G>T (p.Gly335Val)

Gene:
LDLR:low density lipoprotein receptor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
19p13.2
Genomic location:
Preferred name:
NM_000527.5(LDLR):c.1004G>T (p.Gly335Val)
Other names:
NM_000527.5(LDLR):c.1004G>T; p.Gly335Val
HGVS:
  • NC_000019.10:g.11110715G>T
  • NG_009060.1:g.26335G>T
  • NM_000527.5:c.1004G>TMANE SELECT
  • NM_001195798.2:c.1004G>T
  • NM_001195799.2:c.881G>T
  • NM_001195800.2:c.500G>T
  • NM_001195803.2:c.623G>T
  • NP_000518.1:p.Gly335Val
  • NP_000518.1:p.Gly335Val
  • NP_001182727.1:p.Gly335Val
  • NP_001182728.1:p.Gly294Val
  • NP_001182729.1:p.Gly167Val
  • NP_001182732.1:p.Gly208Val
  • LRG_274t1:c.1004G>T
  • LRG_274:g.26335G>T
  • LRG_274p1:p.Gly335Val
  • NC_000019.9:g.11221391G>T
  • NM_000527.4:c.1004G>T
  • c.1004G>T
Protein change:
G167V
Links:
LDLR-LOVD, British Heart Foundation: LDLR_000335; dbSNP: rs869320650
NCBI 1000 Genomes Browser:
rs869320650
Molecular consequence:
  • NM_000527.5:c.1004G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195798.2:c.1004G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195799.2:c.881G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195800.2:c.500G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195803.2:c.623G>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Cardiovascular phenotype
Identifiers:
MedGen: CN230736

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002710223Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Likely pathogenic
(Sep 14, 2017)
germlineclinical testing

PubMed (10)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands.

Lombardi MP, Redeker EJ, Defesche JC, Kamerling SW, Trip MD, Mannens MM, Havekes LM, Kastelein JJ.

Clin Genet. 2000 Feb;57(2):116-24.

PubMed [citation]
PMID:
10735632

Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent.

Wang J, Huff E, Janecka L, Hegele RA.

Hum Mutat. 2001 Oct;18(4):359.

PubMed [citation]
PMID:
11668627
See all PubMed Citations (10)

Details of each submission

From Ambry Genetics, SCV002710223.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (10)

Description

The p.G335V variant (also known as c.1004G>T), located in coding exon 7 of the LDLR gene, results from a G to T substitution at nucleotide position 1004. The glycine at codon 335 is replaced by valine, an amino acid with dissimilar properties. This alteration, also known as G314V, has been reported in familial hypercholesterolemia (FH) cohorts in the Netherlands and Spain (Lombardi MP et al. Clin. Genet., 2000 Feb;57:116-24; van der Graaf A et al. Circulation, 2011 Mar;123:1167-73; Alonso R et al. Clin. Biochem., 2009 Jun;42:899-903; Huijgen R et al. Eur. Heart J., 2012 Sep;33:2325-30). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Another alteration affecting the same amino acid, G335S, has been described in a number of FH cohorts (Hobbs HH et al. Hum. Mutat., 1992;1:445-66; Wang J et al. Hum. Mutat., 2001 Oct;18:359; Laurie AD et al. Atheroscler Suppl, 2004 Dec;5:13-5; Bertolini S et al. Atherosclerosis, 2013 Apr;227:342-8; Rabacchi C et al. J Clin Lipidol Apr;10:944-952.e1; Bañares VG et al. J Clin Lipidol Feb;11:524-531). Based on the majority of available evidence to date, this variant is likely to be pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024